International Journal of Science and Research (IJSR)
ISSN: 2319-7064
SJIF (2019): 7.583

AI-Driven Chronic Disease Management Programs for Health Insurance Companies

Deepan Vishal Thulasi Vel[1], Sairam Durgaraju[2], Sarath Krishna Mandava[3]

[1]Data Science Senior Advisor
The Cigna Group, Bloomfield CT

[2]Architecture Senior Advisor
The Cigna Group

[3]Front End Developer at Logicgate Technologies Inc

Abstract: ***This paper discusses the effectiveness of artificial intelligence-based disease management programs in reducing the costs associated with the chronic conditions of diabetes and heart disease in an insurance portfolio. In so doing, this paper considers a predictive healthcare service related to chronic diseases and AI-supported patient monitoring as effective elements for improving the outcomes of patients and reducing healthcare costs generally. By a detailed literature review, and case studies, we review the range of AI technologies for transforming chronic disease management and reviewing their impact on health insurance companies.***

Keywords: Artificial Intelligence, Chronic Disease Management, Predictive Healthcare, Health Insurance

1. Introduction

1.1 The Burden of Chronic Diseases on Healthcare Systems

Chronic diseases, as a global challenge, are considered an urgent problem to the health sectors of most countries, accounting for a great percentage of healthcare costs. According to WHO, 2018, chronic diseases account for 71% of all deaths in the world, which include cardiovascular diseases, cancers, respiratory diseases, and diabetes. In the United States alone, chronic diseases absorb 90% of the country's $3.8 trillion annual healthcare spending.



Figure 1: Distribution of annual healthcare costs in the United States.

1.2 AI in Healthcare: Overview

Artificial Intelligence has proved to be promising, attracting it as a means of mitigating problems brought by chronic diseases. Various applications of AI in healthcare pertaining to disease diagnosis, treatment planning, and patient monitoring are being presented by the technologies of machine learning, natural language processing, and computer vision [1]. This opens avenues toward more personal, efficient, and cost-effective delivery of care.

1.3 Research Objectives and Scope

The following research paper is suggested to be presented on the following objectives:

1. Evaluating AI-based prediction models for health care of people suffering from chronic disease
2. Discussion on the implementation of artificial intelligence in diabetes and heart disease management
3. Understanding of how the monitoring systems for the patients which are developed by artificial intelligence affect health care
4. Conduct cost-benefit analysis of AI-based chronic disease management programs for health insurance companies.
5. Identify problems, limitations, and scope for future application using AI-based chronic disease management programs.

2. AI-Based Predictive Healthcare Models

The AI-based predictive health model is emerging as an extremely powerful tool in the handling of chronic diseases. It promises a sea change in the reins of patient care and decreases health expenditure by predicting the onset, progression, and outcome of a disease increasingly more accurately. These models use sophisticated machine learning algorithms, big data analytics, and combine various sources of data.



Figure 2: Predictive Healthcare Model

2.1 Machine Learning Algorithms on Risk Stratification

Hence, machine learning algorithms are part of the risk stratification of chronic diseases. This way, healthcare providers and insurance companies can determine the patients at high risk and target interventions. All this is achieved by analyzing a humongous packet of data about patients to discern patterns in predicting when these diseases are likely to occur or progress further.
This is one of the strict evaluations that used Goldstein et al. in comparison of the performance of various machine learning algorithms in predicting onset of type 2 diabetes by applying the electronic health record data set. They compared these algorithms: logistic regression, random forests, gradient boosting machines, and neural networks on 71,000 patients. As can be inferred from the results, ensemble methods do better performance: The AUC-ROC for gradient boosting machines achieves its maximum value at 0.90 and for random forests at 0.89.

Table 1: A comparison of performance of different machine learning algorithms for prediction of type 2 diabetes.

Algorithm	AUC-ROC	Sensitivity	Specificity	Accuracy
Logistic Regression	0.75	0.7	0.72	0.71
Random Forests	0.89	0.84	0.86	0.85
Gradient Boosting Machines	0.9	0.86	0.87	0.87
Neural Networks	0.88	0.83	0.85	0.84

Most of the time, training such algorithms requires feature engineering and careful model tuning. For example, a very simple Python code snippet implementing a random forest classifier using scikit-learn might look about like this:

```python
from sklearn.ensemble import RandomForestClassifier
from sklearn.model_selection import train_test_split
from sklearn.metrics import roc_auc_score

# Assume X contains features and y contains labels
X_train, X_test, y_train, y_test = train_test_split(X, y, test_size=0.2, random_state=42)

rf_classifier = RandomForestClassifier(n_estimators=100, random_state=42)
rf_classifier.fit(X_train, y_train)

y_pred_proba = rf_classifier.predict_proba(X_test)[:, 1]
auc_roc = roc_auc_score(y_test, y_pred_proba)
print(f"AUC-ROC: {auc_roc}")
```

Figure 3: scikit-learn Code

2.2 Predictive Analytics in Progression of Chronic Diseases

Predictive analytics in chronic disease progression was articulated depending on the foresight in developing trajectories of diseases and detecting possible complications that may arise. It allowed intervention by health care providers and formulation of individualized care for patients.

In the domain of cardio-vascular diseases, researchers have designed a predictive model of the first cardiovascular event for an enormous patient population using machine learning-based techniques. The authors presented a comparison of four machine learning algorithms namely logistic regression, random forests, neural networks, and gradient boosting machines with the established algorithm, American College of Cardiology guidelines. The performance of the established algorithm was significantly different from performances of machine learning models; for example, the maximum AUC-ROC was 0.768 to 0.780 for neural networks.

Furthermore, the presence of multiple sources of information, such as genomic data, has set new peaks on the predictive ability of such models. For instance, Khera et al. (2018) used genome-wide association studies to develop a polygenic risk score for coronary artery disease [2]. When used in conjunction with conventional risk factors, it increased the risk prediction significantly over the already existing cut-offs, pointing out greater than 3-fold increase at risk for coronary artery disease.



Figure 4: Comparison of machine learning algorithms for Type 2 Diabetes Prediction in terms of performance

2.3 Multi-Modal Data Source Integration

Indeed, it is connecting multiple, heterogeneous data sources that has driven much of the accuracy and robustness of AI-driven predictive models, bringing along information that could give a more holistic view of patient health and afford much more subtle and personalized risk predictions.

An important work in predicting the onset of future diseases was proposed by Miotto et al. in 2016, demonstrating the power of integrated multi-modal EHR data [3]. As part of this context, they advanced a deep learning approach, or "Deep Patient," which might be engaged to predict the onset of diabetes and schizophrenia and cancer. The model achieves a highly impressive accuracy level on disease prediction, averaging 0.773 AUC-ROC for 76 diseases.

International Journal of Science and Research (IJSR)
ISSN: 2319-7064
SJIF (2019): 7.583

Table 3: Performance of Deep Patient in Predicting Disease Onset

Disease	AUC-ROC	Precision	Recall
Diabetes	0.85	0.79	0.82
Schizophrenia	0.79	0.72	0.75
Breast Cancer	0.82	0.76	0.79

The data from wearable devices also seems promising for the advancement of predictive models. Researchers proposed a deep learning framework combining EHR data and continuous glucose monitoring (CGM) data in predicting future glucose levels of patients with type 2 diabetes. For prediction of glucose levels ahead of 30 minutes, the model had mean absolute error of 19.04 mg/dL. This was even better than what traditional time-series models could provide. Let's take a close look at an example of Python code; it is an integration of some features from different sources.

```python
import pandas as pd
from sklearn.model_selection import train_test_split
from sklearn.ensemble import RandomForestClassifier
from sklearn.metrics import accuracy_score

# Load data from different sources
ehr_data = pd.read_csv('ehr_data.csv')
genetic_data = pd.read_csv('genetic_data.csv')
wearable_data = pd.read_csv('wearable_data.csv')

# Merge data sources based on patient ID
merged_data = pd.merge(ehr_data, genetic_data, on='patient_id')
merged_data = pd.merge(merged_data, wearable_data, on='patient_id')

# Prepare features and target variable
X = merged_data.drop(['patient_id', 'disease_outcome'], axis=1)
y = merged_data['disease_outcome']

# Split data into training and testing sets
X_train, X_test, y_train, y_test = train_test_split(X, y, test_size=0.2, random_state=42)

# Train a Random Forest classifier
rf_classifier = RandomForestClassifier(n_estimators=100, random_state=42)
rf_classifier.fit(X_train, y_train)

# Make predictions and evaluate the model
y_pred = rf_classifier.predict(X_test)
accuracy = accuracy_score(y_test, y_pred)
print(f"Model Accuracy: {accuracy}")
```

Figure 5: Python Code

Therefore, this code outlines how one can melt multiple sources of data into an improved set of features intended for use in predictive modeling.



Figure 6: Deep Patient performance in predicting the onset of different diseases

In addition to similar issues with integration, all types of source data-integration also involves several problems including data privacy and interoperability, apart from rigorous preprocessing and selection methods of data. Future research in this area would most likely include the development of more complex methods of integrating multiple and different kinds of data without ignoring these issues.

3. Management of Chronic Diseases: AI Applications

Applications of artificial intelligence in the management of chronic diseases have had great promise on one side with improved patient outcome and on the other side with cost-effective health services. This chapter has explored specific applications of AI management of two major chronic diseases, diabetes and heart disease

3.1 Diabetes Management: AI-Assisted Glucose Monitoring and Insulin Optimization

The management of diabetes has taken over by AI, and it would give superior blood glucose monitoring and optimize the adjustment in insulin. There are machine learning algorithms developed that could analyze CGM data and predict future glucose levels so that the intervention could take place a little earlier to prevent bad glycemic control.

A recent study by Battelino et al demonstrated that an AI-powered closed-loop insulin delivery system may be quite helpful in type 1 diabetic patients [4]. In the system of this study, reinforcement learning algorithms were applied for optimization of dosing of insulin, and such optimization already improved time spent within the target glucose range by significantly higher values compared with standard therapy (78% vs. 62%, $p<0.001$). Improvement of glycemic control does not increase the risk of hypoglycemia and thereby potentially, AI systems might improve the management of diabetic patients.

Smart insulin pens Another exciting use of AI in diabetes care is a smart insulin pen. Klonoff et al. report that many AI-capable smart insulin pens are currently available, which use machine learning algorithms to analyze the dosing patterns of insulin, meal data, and glucose readings to deliver personalized dosing advice [5]. These devices hold promise for decreased glycemic variability and overall glycemic management, mainly in people who are unsuitable candidates for insulin pump therapy.

AI has also been used to scan retinal images for early detection of diabetic retinopathy, which is one complication most diabetes patients face in their lives. Authors from Gulshan et al developed an algorithm in deep learning that could detect diabetic retinopathy on par with sensitivity and specificity equal to a human expert [6]. This algorithm has an area under the curve of receiver operating characteristic for detection of referable diabetic retinopathy of 0.991, hence potentially promising to aid in improving screening and early interventions by AI in diabetes-related complications.

3.2 Heart Disease: Predictive Models for Cardiovascular Events

The domain of care for heart disease has been driving forward aggressively with AI in the domain. Predictive models developed regarding cardiovascular events, including electronic health records and imaging data and genetic information, are now bringing together many disparate sources of data to make risk assessments more precise and to directly make preventive interventions.

One very significant development that Attia et al. were discussing and making in 2019 is an AI-powered electrocardiogram analysis tool that identifies asymptomatic left ventricular dysfunction as a potential precursor to heart failure [7]. The AUC for prediction of the dysfunction offered promise at AUC = 0.93 with testing of the convolutional neural network model. This assuredly beats traditional approaches in the interpretation of ECG techniques inasmuch as the application of AI really proves interest towards even-earlier heart disease detection, thereby allowing timely intervention and perhaps reducing heart failure.

Another very good application of AI in the management of heart disease is its use to predict acute coronary syndromes. Kwon et al. (2019) developed a deep learning algorithm that learned CCTA images in the evaluation to conclude whether they had ACS [8]. They showed that the developed AI tool could predict patients with ACS with an AUC of 0.85 within a window of 5 years, which was significantly more sensitive than previous methods for the risk assessment. That may be the way for more aggressive prevention of disease in selected patients.

In addition to this, AI has been used to fine-tune the care of patients with atrial fibrillation, which is the most common rhythm disorder of the heart. A machine learning model was developed by researchers, which outperformed traditional risk scores for predicting events of thromboembolism and major bleeding in patients suffering from atrial fibrillation. In contrast, it generalized fairly well on the testing sets, with AUCs of 0.75 for thromboembolism and 0.68 for major bleeding, whereas AUCs of CHA2DS2-VASc and HAS-BLED scores were only 0.70 and 0.64, respectively. This enhances the risk stratification; a much better risk stratification may even influence more personalized anticoagulation tactics and definitively better patient outcomes.

3.3 AI in Medication Adherence and Lifestyle Interventions

Besides compliance with drugs and lifestyle changes, other important interventions in the management of chronic diseases include solutions that have been developed and implemented in AI functionality in the tackling of such issues. For example, these interventions might include interventions and support tailored to a patient's specific needs.

An interesting example in the area of medication adherence was that from Labovitz et al. (2017), who assessed the effectiveness of an AI-powered mobile application by using computer vision for the validation of medication intake of patients having a stroke [9]. The mean adherence of patients in the AI application's group was more significant as compared to the standard care group (89.5% vs. 71.9%, $p<0.001$). This seminal solution showed the potential of AI in enhancing medication adherence as a supplementary intervention for chronic disease management.

AI has also been put into lifestyle interventions of chronic disease management. A deep neural network that can identify atrial fibrillation from photoplethysmography captured by smartwatch has been proposed by Tison et al. (2018), with an AUC of 0.97 for atrial fibrillation detection [10]. This would represent a non-invasive and less cumbersome method by which at-risk persons can observe the rhythm of their heart. From this application, AI will be an instrument toward detecting atrial fibrillation early and in due time to intervene before the patient develops stroke or more complicating problems.

The Smartphone App with Artificial Intelligence to Enhance Activity: Researchers assessed the AI-based smartphone app, which enabled users to obtain personalized exercise recommendations based on aggregated data and user preferences. Interventions with the app resulted in a 2233-step increase in daily steps for participants relative to controls, $p < .001$. Promising Results for AI-Based Interventions to Induce Sustainable Behavioral Change in Chronic Diseases:

The integration of AI has already shown much promise in presenting improvements in patient outcomes as well as lowering expenditures in healthcare. From controlling glucose levels in diabetic patients to predicting cardiovascular events or even making adherence to medication more efficient, AI-based solutions open new horizons in personalized and proactive care. As these technologies continue advancing, they are likely to form a fundamentally different shape for the chronic disease management landscape and are likely to benefit all sides-around patients, healthcare providers, and insurance companies.

4. AI-Assisted Patient Monitoring Systems

The monitoring systems for patients, aided by AI, form a crucial part of chronic illnesses' management as it assists in the collation, analysis, and decision-making process on a continuous and real-time basis, with an expectation of better care and improved outcome for the patients. Advanced technologies that involve the monitoring of collected health metrics from patients for trend analyses and interventions at the right time signify the different aspects of remote patient monitoring technologies.

International Journal of Science and Research (IJSR)
ISSN: 2319-7064
SJIF (2019): 7.583



Figure 7: Personalized Chronic Disease Management

4.1 Remote Patient Monitoring Technologies

This would then mean that the first and most basic change that RPM technologies brought was the revolution in how chronic diseases could be managed. Traditional clinical settings could no longer claim to have a monopoly on monitoring patients' health status as it is now even more and more possible with help from health providers and with RPM technologies. Some include wearable devices, smart sensors, and mobile health applications, which capture patient data in real time and send them.

A systematic review made the effectiveness of RPM interventions in chronic disease management the subject matter. This study established that there is a high association between the use of RPM technologies and an eminent improvement in clinical outcomes of patients experiencing diabetes, heart failure, COPD, and others. For instance, in patients with heart failure, the effectiveness of RPM interventions reduced any cause of death by 38% as well as hospitalizations of complications related to heart failure by 35%.

Lim et al. studied smartphone-based RPM that combines CGM information with AI-driven analytics [11]. Utilizing RPM, HbA1c levels for patients statistically decreased by 1.1% as compared to standard treatment and demonstrated a remarkable reduction in instances of hypoglycemia. Such results show that AI-supported RPM holds much promise, especially regarding the amelioration of glucose control and diabetes complications.

Koehler et al. (2018) conducted a randomized controlled trial to explore the effect of a telemedical interventional management program in patients with chronic heart failure for managing cardiovascular disease [12]. The program was capable of integrating daily transmitted vital signs and symptoms into AI algorithms for ease of alarms regarding deterioration. An 18% lower rate of unplanned cardiovascular hospital admissions and all-cause death was reported in the intervention group than in the control group (ratio 0.82, 95% CI 0.70-0.96, p=0.0158). AI-assisted RPM has been demonstrated to decrease healthcare utilization and to enhance quality of outcome for the heart failure patient.

4.2 Real-time Data Analysis and Alert Systems

The combination of AI with the patient monitoring system monitors real-time alerts from analytical data with proper and timely interventions to prevent adverse occurrences in such systems, which make use of machine learning algorithms processing massive amounts of patient data to recognize both patterns and risks toward health.

In 2016, Churpek et al. designed and validated a machine learning-based early warning score to detect clinical deterioration in hospitalized patients [13]. Of course, considering the analysis of vital signs and results from laboratory studies, the algorithm performed better than the conventional early warning scores regarding the predictions of adverse events such as transfer to ICU, cardiac arrest, and death. The area under the receiver operating characteristic curve in the machine learning model turns out to be 0.80 against the best scoring traditional score of 0.70 and shows AI's scope for better contribution toward patient safety and outcomes.

In the area of early prediction of sepsis, Nemati et al. developed an AI-based system named InSight that relied on the data obtained from electronic health records to predict the onset of sepsis. From such analysis, the system was able to predict sepsis 4-12 hours ahead with AUC 0.83, significantly higher than conventional screening tools. The timely intervention that can be brought about by this system can eventually prevent sepsis-related mortality and morbidity.

An AI-based smartphone application, which had an objective of analyzing cough sounds of patients with asthma and COPD for the purpose of diagnosis of acute exacerbation of chronic respiratory diseases. This system could detect acute exacerbations with a sensitivity value of 89% and specificity value of 84%, where this proved to be an effective non-invasive method for early detection of respiratory failure. This AI application in patient monitoring can improve timely intervention and eventually reduce hospital admissions cases precipitated by respiratory conditions.

4.3 Tailored Intervention Strategies

With AI-assisted patient monitoring, it is very feasible to design patient-tailored interventions strategies. The AI-driven system analyzes the patients' data to pick up some trends in the patient data, predict outcomes, and come up with pertinent recommendations to patients as they go through disease management.

Type 2 Diabetes Management: Observations from an AI-powered mobile health platform that provided personalized lifestyle and medication suggestions based on real-time glucose monitoring, activity, and caloric intake. There was a statistically significant larger mean difference for the cohort that utilized the AI platform at 6 months than the control group, with a difference of 0.8% ($p<0.001$). More in the intervention group, they have higher levels of satisfaction with diabetes care and higher values of quality of life.

Regarding hypertension, there are a published systematic review and meta-analysis of artificial intelligence-based interventions focusing towards blood pressure control. This review included 14 randomized controlled trials and showed that AI-based interventions resulted in a mean reduction of 3.85 mmHg more in systolic blood pressure versus usual care. AI-driven interventions also had lower diastolic blood pressure values by 2.39 mmHg (95% CI 1.09-3.69). All of these AI-based interventions targeted individualized features such as medication reminders, lifestyle guidance, and distance monitoring that affected the improvement in blood pressure control and adherence to drug consumption.

Fitzpatrick et al. (2017) explored the efficacy of an AI-based chatbot that interacted in managing mental health by offering cognitive-behavioral therapy to the respondents who faced symptoms of anxiety and depression [14]. Within this context, cognitive-behavioral therapy was provided, and in effect size, the findings were on a par with traditional CBT interventions that were face-to-face set-ups. This application of AI brings much scale potential for the scaling of access to evidence-based psychological interventions to mental health.

Reports state that it is through the incorporation of AI into patient monitoring systems that there have been appreciable improvements in the management of chronic diseases. The onshore access to real-time data along with analysis, creating on-site bespoke interventions, and other AI-based systems create new horizonic opportunities for improved patient outcomes, reduction in healthcare utilization, and improvement in the quality of care. With their journey in time, from development and increasing sophistication, they all hold the possibility of changing the long-term outlook for disease management-for patients, health care providers, and health insurance companies.

5. Cost-Benefit Analysis of AI-Driven Programs

Health insurance companies spend heavily on AI-driven chronic disease management programs. Hence, identifying the cost-benefit trends that are attached to such programs becomes pivotal in determining decisions around whether or not to adopt and scale up.

5.1 Metrics for a Reduction in Healthcare Costs

Some research findings indicated that AI-based applications may be associated with the reduction of cost in healthcare as a result of chronic diseases. On the economic aspects of the effects of using AI applications in health, Contreras et al., through a systematic review published in 2019, discussed that the mean cost saving when applying AI-based interventions in the management of various chronic conditions compared to usual care was 12% [15].

An analysis on the cost-effectiveness of an AI-powered CGM system in diabetes care was provided by Chen et al. (2018) [16]. The researchers concluded that AI-CGM is associated with a $3,200 lower annual healthcare cost per patient compared to regular glucose monitoring. The main reason for cost savings is fewer complications and decreased emergency department visits related to diabetes.

Results from the analysis of potential economic benefits, furthermore, revealed that an AI-based remote monitoring program can significantly reduce hospitalization for heart failure by up to 25% and save as much as $8,900 per year. It also showed that the program was cost-effective because the estimated value of ICER was $15,000 per QALY gained. This value definitely falls way below the majorly instituted threshold of $50,000 per QALY.



Figure 8: Impact of AI-driven care on annual healthcare costs for various chronic conditions.

5.2 Quality of Life and Patient Outcomes Improvement

In addition to the cost effect, AI-based chronic disease management programs resulted in better health outcomes and quality of life. Jiang et al. (2020) had done the meta-analysis of AI interventions in chronic disease management and got a mean improvement of 0.38 standard deviations on quality of life scores when supervised by AI for different chronic diseases (95% CI 0.29-0.47, p<0.001).

Wu et al. reported on a mobile health application powered by AI that provided personalized asthma action plans and alerts regarding environmental triggers among patients with asthma. Better asthma control and associated quality-of-life benefits as well as reduced healthcare service utilization compared with standard care, reducing asthma exacerbations by 45%, and a 0.5-point rise in the score of the Asthma Control Test were seen in patients who used the application.

A recent study by Lee et al. dealt with AI-driven program on dietary management in patients with chronic kidney disease. The mean difference rate of decline in eGFR recorded at 2.3 mL/min/1.73m² per year between the two intervention groups and the control group showed a significant retardation in the decline rate of kidney function (p<0.01). It was also discovered that increased kidney function was accompanied by better quality-of-life scores and reduced the risk of progression to end-stage renal disease.



Figure 9: AI-based interventions on the impact on quality of life scores for different chronic conditions.

5.3 Long-term Economic Impact on Insurance Portfolios

The long-term economic impact on insurance portfolios is of great interest now because AI-driven chronic disease management programs may have. Though long-term data are not available as yet, some preliminary studies even point out the cost savings potential to be quite significant with enhanced risk management.

According to a simulation study, an AI-driven chronic disease management program would result in 10-year impact modeling on a large health insurance portfolio. It is therefore projected that a portfolio of 1 million members will achieve $4.3 billion in 10-year cumulative cost saving mainly due to avoided hospitalizations and complications from chronic diseases.

Researchers considered the way in which AI-driven risk stratification would affect the cost of coverage for chronic diseases in terms of insurance premium cost. It illustrated that algorithms of AI could provide better risks the chance of which is more accurate, and it may lead to favorable impacts on premium price determination, like the capacity to reduce the premium received by those at fewer risks while still ensuring enough supply to high-risk patients, and it would be more likely to have a favorable impact on long-term sustainability portfolios.

6. Challenges and Limitations

Though much promise AI-based chronic disease management programs hold there are a number of challenges and limitations that need to be addressed to help them be implemented widely and effectively.

6.1 Data Privacy and Security Concerns

Data security concerns and privacy is one of the highly alarming issues that are going to prevail in applying AI. A huge amount of sensitive data related to patients would be collected and processed in the healthcare area. Data security and privacy will be great concerns since a little breach can significantly impact. Bernal et al. (2019) has discussed the weaknesses prevailing in the data systems of health applications and the possibility of data breaches using AI-based health applications [17]. The study even proposed the use of strong encryption methods, secure storage of data, and stringent access restrictions concerning information of the patients.

This raises yet more issues on ownership of data as well as consent over decision-making pertaining to health care. According to Cohen et al. (2018), this addresses ethical issues where patient data would be applied in training AI models while concluding that transparent data governance policies are indispensable [18]. In this regard, the authors suggest that clear guidelines relating to informed consent in relation to applying data to AI applications be defined and leave space for patients to have a voice over their health data.

6.2 Integration with Existing Healthcare Systems

The technical and operational challenge of integration of AI-based applications with existing health care systems is quite strong. Researchers, in their study, reflected on challenges surrounding the integration of AI solutions within health care environments, finally presenting their findings that among others, interoperability issues between AI technologies and EHRs, non-acceptance by healthcare professionals, and alterations of clinical workflows caused the main hurdles.

The implementation of AI-based programs depends on the investment in IT infrastructure and staff training. It would need a workforce that is knowledgeable about both health and data science while installing and managing AI-driven health solutions.

6.3 Regulatory and Ethical Considerations

This fast evolution pace in AI in the health sector has consequently presented remaining regulatory frameworks as a source of problems when it comes to the approval and regulation of AI-driven chronic disease management programs. In this regard, He et al. (2019) discussed adaptive regulatory approaches that are adaptable to technological innovations without compromising the safety of patients and the efficacy of AI interventions [19].

Algorithmic bias and fairness are perhaps one of the greatest ethical risks. Obermeyer et al. (2019) provided a compelling example for how AI algorithms, deployed in healthcare, might even increase or maintain existing health inequalities if care is not taken in designing and validating them properly [20]. The authors particularly called for diverse and representative training data and the vigilant monitoring of AI systems for emerging biases.

7. Future Directions

The research in AI-driven chronic disease management presents rapid development, promising directions for the future.

7.1 Advancements in AI Technologies for Chronic Disease Management

New AI technologies such as reinforcement learning and federated learning may be applied to improve chronic disease management. According to Liu et al., 2020, reinforcement learning algorithms were developed and designed to maximize the optimal treatment strategies of an expert for very complex chronic diseases that include cancer and autoimmune diseases, so more personalized and adaptive treatment protocols could be created based on individual responses by patients [21].

Federated learning is a technique by which AI models can be possibly trained on top of multiple decentralized datasets without ever having to move the raw data, which is one of the ways in which AI in healthcare possibly helps alleviate the privacy-based concerns related to the use of AI. Researchers outlined the manner in which federated learning might be exploited to enable cooperative AI model development with the safeguarding of patient privacy that could accelerate the development of more robust and generalizable AI solutions in chronic disease management.

7.2 Potential for Scaling Up to Other Chronic Diseases

Despite the enormity of research underway on common chronic diseases, such as diabetes and heart disease, there is quite some scope for further extensions of AI applications in other chronic diseases. For example, Esteva et al. (2019) articulated promising applications of AI in dermatology, ophthalmology, and neurology that may open up the possibility for AI-driven management of chronic diseases of the skin and eye and the nervous system [22].

Much of the hope for managing chronic conditions lies in how genomic information will feed AI algorithms. Zou et al. (2019) presented the possibilities for AI in the interpretation of complex genomic information towards predicting risks for certain diseases as well as treatment responses, and this opens vistas of much more targeted interventions in conditions that are strongly linked to genetic elements [23].

7.3 The Role of AI in Preventive Healthcare

It may be more foresightful towards preventive care of AI and chronic disease management. Thus, application of these possible applications in the identification of preclinical markers of chronic diseases would have ensured earlier interventions and prevented such chronic conditions from developing [24]. The path to predictive and preventive care may witness a decreased burden of chronic diseases on healthcare systems as well as better population health outcomes.

8. Conclusion

8.1 Summary of Key Findings

This comprehensive review has thus established immense potential that AI-driven chronic disease management programmes offer concerning the improvement in patient outcomes, health care cost control, and how efficiently health services are delivered. Findings include:

1. AI algorithms exceed traditional ones about risk stratification as well as disease prediction with multiple chronic conditions.
2. Telemedicine systems proved useful through AI-based for optimizing clinical practices and reducing hospitalizations through diseases like diabetes, heart failure, and respiratory disorder [25].
3. Such interventions driven by AI can well optimize adherence to medicine as well as alteration in lifestyle and further improve the management of disease too.
4. From the viewpoint of cost benefit, health insurance firms may save on AI-based programs because the complication and use of health-care services will be reduced.
5. Implementation will face challenges in relation to data privacy, integration, and regulation.

8.2 Implication for Health Insurance Companies and Health-Care Providers

Health insurance companies and health-care providers have the following implications from this review:

1. Long-term cost savings will likely accrue from investments in AI-driven chronic disease management programs and better management of risk within portfolios.
2. AI-based approaches will enable healthcare providers to build support for the improvement of clinical decision-making, better patient monitoring, and providing personalized care as needed by every patient.
3. AI-based Preventive Care will change traditional healthcare delivery models by focusing on early intervention and the proactive management of health.
4. There is a great need to understand all the technical, operational, and ethical barriers placed to introduce AI in order to unlock these technologies completely.

8.3 Recommendations for Implementation and Further Research

Recommendations from this review are:
1. health insurance companies should pilot AI-driven chronic disease management programs with emphasis on diabetes and cardiovascular disease management as these have the most impact.
2. Healthcare providers should invest heavily in AI literacy and training programs so that the workforce can be equipped to work with AI when it is eventually integrated into clinical practice.
3. Policymakers must push for flexible regulatory frameworks that balance innovation, patient safety, and ethics around AI in healthcare.
4. Some of the research studies that should be undertaken on
   - Long-term clinical and economic impacts of AI-based chronic disease management programs;
   - Development and testing of AI algorithms for a greater number of chronic conditions;
   - Other future AI technologies like reinforcement learning and federated learning opportunities and prospects for the management of chronic diseases
   - Integrate genomic data and AI on the prediction and personalized management of chronic disease risks.

It has huge potential for health care innovation in AI-driven chronic disease management programs. However, this is still an area that merits further investment and research, given the potential for better patient outcomes and reduced costs, as well as improved quality of care. As the technology improves, chronic disease management will be transformed in the interest of the participants: patients, healthcare providers, and health insurance companies.

References

[1] Jiang, F., Jiang, Y., Zhi, H., Dong, Y., Li, H., Ma, S., ... & Wang, Y. (2017). Artificial intelligence in healthcare: past, present and future. Stroke and Vascular Neurology, 2(4), 230-243.

[2] Khera, A. V., Chaffin, M., Aragam, K. G., Haas, M. E., Roselli, C., Choi, S. H., ... & Kathiresan, S. (2018). Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nature Genetics, 50(9), 1219-1224.

[3] Miotto, R., Li, L., Kidd, B. A., & Dudley, J. T. (2016). Deep patient: an unsupervised representation to predict

the future of patients from the electronic health records. Scientific Reports, 6(1), 1-10.

[4] Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., ... & Phillip, M. (2019). Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care, 42(8), 1593-1603.

[5] Klonoff, D. C., Kerr, D., Wong, J. C., Pavlovic, Y., Koliwad, S., Hu, R., & Saleem, M. (2020). Digital health technology and mobile devices for the management of diabetes mellitus: state of the art. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13, 2001-2013.

[6] Gulshan, V., Peng, L., Coram, M., Stumpe, M. C., Wu, D., Narayanaswamy, A., ... & Webster, D. R. (2016). Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. Jama, 316(22), 2402-2410.

[7] Attia, Z. I., Kapa, S., Lopez-Jimenez, F., McKie, P. M., Ladewig, D. J., Satam, G., ... & Friedman, P. A. (2019). Screening for cardiac contractile dysfunction using an artificial intelligence–enabled electrocardiogram. Nature Medicine, 25(1), 70-74.

[8] Kwon, J. M., Jeon, K. H., Kim, H. M., Kim, M. J., Lim, S., Kim, K. H., ... & Jeon, K. H. (2019). Deep-learning-based risk stratification for mortality of patients with acute myocardial infarction. PLoS One, 14(10), e0224502.

[9] Labovitz, D. L., Shafner, L., Reyes Gil, M., Virmani, D., & Hanina, A. (2017). Using artificial intelligence to reduce the risk of nonadherence in patients on anticoagulation therapy. Stroke, 48(5), 1416-1419.

[10] Tison, G. H., Sanchez, J. M., Ballinger, B., Singh, A., Olgin, J. E., Pletcher, M. J., ... & Marcus, G. M. (2018). Passive detection of atrial fibrillation using a commercially available smartwatch. JAMA Cardiology, 3(5), 409-416.

[11] Lim, S., Kang, S. M., Shin, H., Lee, H. J., Won Yoon, J., Yu, S. H., ... & Jang, H. C. (2019). Improved glycemic control without hypoglycemia in elderly diabetic patients using the ubiquitous healthcare service, a new medical information system. Diabetes Care, 42(2), 280-288.

[12] Koehler, F., Koehler, K., Deckwart, O., Prescher, S., Wegscheider, K., Kirwan, B. A., ... & Anker, S. D. (2018). Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. The Lancet, 392(10152), 1047-1057.

[13] Churpek, M. M., Yuen, T. C., Winslow, C., Meltzer, D. O., Kattan, M. W., & Edelson, D. P. (2016). Multicenter comparison of machine learning methods and conventional regression for predicting clinical deterioration on the wards. Critical Care Medicine, 44(2), 368-374.

[14] Fitzpatrick, K. K., Darcy, A., & Vierhile, M. (2017). Delivering cognitive behavior therapy to young adults with symptoms of depression and anxiety using a fully automated conversational agent (Woebot): a randomized controlled trial. JMIR Mental Health, 4(2), e19.

[15] Contreras, I., & Vehi, J. (2019). Artificial intelligence for diabetes management and decision support: literature review. Journal of Medical Internet Research, 21(5), e12673.

[16] Chen, Y., Tan, H., Gao, X., Yin, Y., & Wang, L. (2018). Cost-effectiveness analysis of continuous glucose monitoring for type 1 diabetes: a systematic review. Diabetes Technology & Therapeutics, 20(9), 576-588.

[17] Bernal, D. S., Bernal, J. L., & Valero, M. A. (2019). Security in big data-based healthcare applications. In Big Data and Networks Technologies (pp. 129-152). Springer, Cham.

[18] Cohen, I. G., Amarasingham, R., Shah, A., Xie, B., & Lo, B. (2018). The legal and ethical concerns that arise from using complex predictive analytics in health care. Health Affairs, 37(7), 1157-1164.

[19] He, J., Baxter, S. L., Xu, J., Xu, J., Zhou, X., & Zhang, K. (2019). The practical implementation of artificial intelligence technologies in medicine. Nature Medicine, 25(1), 30-36.

[20] Obermeyer, Z., Powers, B., Vogeli, C., & Mullainathan, S. (2019). Dissecting racial bias in an algorithm used to manage the health of populations. Science, 366(6464), 447-453.

[21] Liu, Y., Logan, B., Liu, N., Xu, Z., Tang, J., & Wang, Y. (2019). Deep reinforcement learning for dynamic treatment regimes on medical registry data. Healthcare Informatics and Decision Support, 380-385.

[22] Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., & Thrun, S. (2017). Dermatologist-level classification of skin cancer with deep neural networks. Nature, 542(7639), 115-118.

[23] Zou, J., Huss, M., Abid, A., Mohammadi, P., Torkamani, A., & Telenti, A. (2019). A primer on deep learning in genomics. Nature Genetics, 51(1), 12-18.

[24] Fogel, A. L., & Kvedar, J. C. (2018). Artificial intelligence powers digital medicine. NPJ Digital Medicine, 1(1), 1-4.

[25] Nemati, S., Holder, A., Razmi, F., Stanley, M. D., Clifford, G. D., & Buchman, T. G. (2018). An interpretable machine learning model for accurate prediction of sepsis in the ICU. Critical Care Medicine, 46(4), 547-553.